Diagnostic Performance of Ga-68-FAPI-46 PET Scans for Detecting Colorectal Cancer Recurrence in Patients with Elevated Serum CEA During Post-Treatment Follow-Up

What this Trial Is About

Researchers are assessing the effectiveness of Ga-68-FAPI-46 PET scans in detecting the return of colorectal cancer (CRC) in patients who have had surgery and show rising levels of a blood marker called carcinoembryonic antigen (CEA). The trial focuses on improving the detection of cancer recurrence during post-treatment follow-up, especially in patients with stages II and III CRC. This is a phase II, single-center study comparing this new imaging method to the standard F-18-FDG PET scans. Participants will receive both Ga-68-FAPI-46 PET and F-18-FDG PET scans to locate possible recurrent tumors. The Ga-68-FAPI-46 agent targets a protein found in the tumor environment and may provide clearer images due to better tumor uptake and quicker clearance from normal tissues. The study involves 30 participants who have already had or are scheduled for FDG PET scans and will undergo these imaging assessments during the surveillance period after surgery. Throughout the study, participants will be monitored through imaging and clinical follow-ups to confirm the presence or absence of recurrence. Researchers will compare the sensitivity, specificity, and accuracy of both PET scan types within six months of imaging. Safety and data privacy are ensured following Good Clinical Practice guidelines, and participant involvement includes consenting and being able to lie still during the scans.

Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA